Navigation Links
Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
Date:7/20/2009

LAVAL, QC, July 20 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for the new drug application (NDA) submission of its novel formulation of the antidepressant trazodone.

The letter indicates Labopharm's application cannot be approved in its present form due to deficiencies following an FDA inspection of the active pharmaceutical ingredient (API) manufacturing facility, which was completed July 3, 2009. The FDA letter states: "Satisfactory resolution of these deficiencies is required before this application may be approved." No efficacy or safety issues were raised.

The API manufacturer, Angelini, has informed Labopharm that, further to the FDA's complete response letter to Labopharm, in which the FDA raises observations concerning the Drug Master File (DMF) holder in the section "Facility Inspections", Angelini can confirm that the observations raised by the FDA are not critical and that it has not been questioned about the continued supply of trazodone hydrochloride to the U.S. market. Angelini intends to address the observations raised by the FDA in an action plan that Angelini is going to submit to the FDA by July 24, 2009.

"We intend to work closely with the FDA and Angelini to resolve these issues as rapidly as possible," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We continue to prepare for the commercialization of our novel antidepressant and intend to launch in the U.S. market as soon as possible after we receive approval."

The Company will provide further information regarding the timing of its response to the FDA when available.

Labopharm submitted the NDA for its novel formulation of trazodone in September 2008. The NDA is based on data from five pivota
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Reinberg HealthDay Reporter MONDAY, ... all children aged 6 months and older be vaccinated for ... updated their influenza vaccine recommendations to advise that the youngest ... immunity. The AAP also wants parents of children aged 2 ... vaccine instead of the flu shot if it,s readily available. ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... 2014 (HealthDay News) -- Scans of young children,s ... read. This finding could potentially allow doctors to ... early on, preliminary research suggests. "Early identification ... dyslexia as well as most neurodevelopmental disorders," the ... professor of child and adolescent psychiatry at University ...
(Date:9/22/2014)... September 22, 2014 In a continued ... Jeep Dodge Ram is launching an awareness campaign inspired ... (#blindeggchallenge or #ffbBEC) aims to raise awareness and funds ... throwing an egg in the air and trying to ... others and if a nominee does not complete the ...
Breaking Medicine News(10 mins):Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... Agency Region 5 this week nears completion of a $1 ... Louis Park, Minn., A pair of open house-style meetings ... 2 to 4 p.m. and 6 to 8 p.m., at ... St. EPA,s,storefront office at 6528 W. Lake St., Ste. F., ...
... Institute July 18-20, WASHINGTON, June 17 ... health plans and health networks wrestling with,market demands ... of,credentialing services., (Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO ), ... AHIP Institute, June 18-20,in San Francisco. URAC is ...
... get to its destination can mean life or death. ... services to people in need as efficiently as possible, ... three Cornell researchers are tackling in groundbreaking ways. , ... allowing associate professor of operations research Shane Henderson, assistant ...
... reported a 44-year-old woman who presented with upper right abdominal ... lobe, histopathological diagnosis of the isodensity mass in segment V ... hepatic and gumma, respectively. , This study, performed by a ... research article to be published on March 28, 2008 in ...
... to be Available for Interviews to,Discuss his Personal ... of Risks, WASHINGTON, June 17 The ... placed the public health crisis of,sudden cardiac arrest ... conversations and physicians, offices around the country., ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader ... networks and imaging facilities announced,today that Chuck Jett, ... 2nd Annual Healthcare Conference on June 24-26, 2008. ... AM ET. The presentation will be,webcast at ...
Cached Medicine News:Health News:St. Louis Park Vapor Systems Installation Nearly Complete; Meeting July 10 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 3Health News:Cornell efficiency experts seek to save precious minutes in deploying ambulances 2Health News:How to diagnose peliosis hepatis 2Health News:Tim Russert's Death Provides Important Opportunity for News Media to Increase Public Awareness of How to Prevent Sudden Cardiac Arrest 2
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) will ... ended July 31, 2014 on Monday, September 29 before the ... results at 11:00 AM ET. Participating in the call will ... Krakauer , President and CEO; Jorgen B. Hansen , ... Senior Vice President, CFO and Treasurer; and Seth Yellin ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... Statistically Significant and Clinically Relevant, Results ... Neuropathy, SAN FRANCISCO, June 8 Sangamo ... presentation of encouraging Phase,1b clinical data from its ... the American Diabetes Association (ADA). As,disclosed in an ...
... Control Are, Not Statistically Significant but Show Favorable Trend in Reducing Most ... ... FRANCISCO, June 8 Findings from the Veterans,Affairs Diabetes Trial (VADT), a ... today at the 68th Scientific Sessions of the American Diabetes,Association (ADA). According ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 9Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 2Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 3Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 4
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Rigid Endoscopes....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: